Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel for HER2-negative metastatic breast cancer with unresectable brain metastases
ISRCTN79877830Phase 2Completed
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust (UK)
- Start
- Mar 2012
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in breast cancer and brain metastases, sponsored by The Clatterbridge Cancer Centre NHS Foundation Trust (UK). Primary endpoint: Overall proportion surviving at 18 weeks from registration. Started Mar 2012; status: completed.
02
Drugs
cabazitaxel
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ISRCTN79877830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN79877830.